Home / Health / Roche Drug Extends Lung Cancer Survival by Six Months
Roche Drug Extends Lung Cancer Survival by Six Months
25 Oct
Summary
- Roche's experimental drug divarasib significantly improved survival for lung cancer patients.
- Patients treated with divarasib lived nearly six months longer than others.
- The drug showed superior results compared to Amgen and Bristol-Myers Squibb medications.
A promising new drug from Roche Holding AG, identified as divarasib, has shown remarkable efficacy in treating a form of lung cancer that has metastasized.
Clinical trial results indicated that patients administered divarasib experienced a survival advantage of nearly six months when compared to those undergoing treatment with established medications.
This experimental therapy outperformed rival treatments, including Amgen Inc.'s sotorasib and Bristol-Myers Squibb Co.'s ...
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
